Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

87°
- Benton, AR (72018)
  Today
  
  Mostly sunny. High 94F. Winds light and variable..
  
  Tonight
  
  Clear to partly cloudy. Low near 70F. Winds light and variable.
  
  Updated: August 27, 2026 @ 12:42 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

125.73 -2.00 (-1.57%)

Streaming Delayed Price Updated: 11:32 AM EDT, Aug 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

May 05, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

May 04, 2022

From Incyte

Via Business Wire

4 Analysts Have This to Say About Incyte ↗

May 04, 2022

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Via Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance ↗

May 03, 2022

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Incyte: Q1 Earnings Insights ↗

May 03, 2022

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 03, 2022

From Incyte

Via Business Wire

Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M ↗

May 02, 2022

Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland ↗

March 23, 2022

The

Via Benzinga

3 Nasdaq Stocks to Buy Now for Growth ↗

May 01, 2022

These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.

Via InvestorPlace

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

April 28, 2022

From Incyte

Via Business Wire

EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting ↗

April 22, 2022

Via Benzinga

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

April 22, 2022

From Incyte

Via Business Wire

How To Attend Incyte Q1 2022 Earnings Conference Call ↗

April 21, 2022

Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live...

Via Benzinga

Incyte to Report First Quarter Financial Results

April 12, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

This Favorable Sign Appears On Incyte's Chart ↗

April 05, 2022

If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder ↗

March 28, 2022

Incyte Corporation (NASDAQ: INCY)

Via Benzinga

Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks ↗

March 28, 2022

At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)

Via Benzinga

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

March 26, 2022

From Incyte

Via Business Wire

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

March 25, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

March 18, 2022

From Incyte

Via Business Wire

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder ↗

March 14, 2022

The FDA has extended the review period for Incyte Corporation's (NASDAQ: INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo...

Via Benzinga

Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo

March 14, 2022

From Incyte Corporation

Via Business Wire

Insiders Buy More Than $80M Of 3 Stocks ↗

March 11, 2022

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades.

Via Benzinga

Why Are Company Insiders Buying These 7 S&P 500 Stocks? ↗

March 08, 2022

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying...

Via Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients ↗

March 03, 2022

According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in...

Via Benzinga

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval ↗

March 01, 2022

The FDA approved CTI BioPharma Corp's (NASDAQ: CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Sections

Services

Follow Us